{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-010190","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.604127+00:00","generated_at":"2026-05-24T01:40:30.643121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Talphera reports Q4 2024 net loss $1.9M; FDA cuts NEPHRO study size to 70 patients","bullets":["FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; study completion targeted by end of 2025.","Cash and investments of $8.9M at Dec 31, 2024; additional $14.8M private placement financing announced.","Q4 2024 net loss from continuing operations $1.9M ($0.07 per share) vs $4.5M ($0.25) in Q4 2023.","Combined R&D and SG&A expenses decreased to $3.0M in Q4 2024 from $4.6M in Q4 2023.","2025 cash operating expense guidance of $18M-$19M, includes costs to complete NEPHRO study."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-010190","json":"https://secwatch.observer/filing/0001437749-25-010190.json","markdown":"https://secwatch.observer/filing/0001437749-25-010190.md","text":"https://secwatch.observer/filing/0001437749-25-010190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925010190/0001437749-25-010190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925010190/acrx20250330_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:40:30.643121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}